ReviewMolecules (Basel, Switzerland)2026
Small Activating RNAs: A Curated Database and an Overview of Rational Design Principles.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
RNA activation (RNAa), mediated by small activating RNAs (saRNAs), upregulates endogenous gene expression through recruitment of the Argonaute proteins to the promoter, natural antisense transcripts, or other noncoding RNAs. This mechanistically distinct modality addresses an unmet need, as few RNA therapeutics currently function to activate endogenous gene expression. Three saRNA therapeutics are now in clinical trials; however, broader application remains constrained by largely empirical candidate screening and limited design guidelines, particularly in terms of saRNA targets. Unlike siRNAs, for which extensive sequence-activity relationships and computational design strategies exist, saRNA activity remains comparatively difficult to predict. Here, we assembled an updated and annotated database of publicly available saRNA sequences and paired it with an overview of the RNAa principles, the clinical and preclinical landscape of saRNA utility and current saRNA design guidelines. Finally, we outline opportunities for artificial intelligence-assisted rational design, highlighting how machine learning trained on curated saRNA datasets could accelerate discovery of novel saRNA candidates. Consolidation of saRNA records into a unified resource will hopefully enable systematic analysis of sequence features associated with activity and lay a foundation for moving saRNA design from largely empirical screening toward more rational design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.